Feasibility Trial on Combination of Platinum Doublets and Hypofractionated Radiotherapy for Locally-advanced Stage and / or Inoperable Non-small Cell Lung Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms HYPOLAN
- 28 Nov 2017 Planned End Date changed from 1 Jan 2022 to 2 Nov 2017.
- 28 Nov 2017 Planned primary completion date changed from 1 Jan 2020 to 2 Nov 2017.
- 28 Nov 2017 Planned initiation date changed from 1 Jan 2018 to 1 Nov 2017.